Lombard Odier Asset Management (USA)’s Lipocine LPCN Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2016
Q2
Sell
-6,984
Closed -$1.08M 221
2016
Q1
$1.21M Sell
6,984
-5,408
-44% -$923K 0.16% 127
2015
Q4
$2.72M Sell
12,392
-5,010
-29% -$1.05M 0.26% 109
2015
Q3
$3.5M Sell
17,402
-12,986
-43% -$3M 0.31% 110
2015
Q2
$4.43M Buy
30,388
+6,859
+29% +$851K 0.32% 117
2015
Q1
$2.76M Hold
23,529
0.22% 122
2014
Q4
$2.1M Hold
23,529
0.14% 138
2014
Q3
$2.44M Buy
23,529
+588
+3% +$73.1K 0.17% 137
2014
Q2
$2.38M Buy
+22,941
New +$2.74M 0.13% 146

Other funds holding LPCN

Lombard Odier Asset Management (USA)'s LPCN Position: Q2 2016 in Review

Lombard Odier Asset Management (USA) sold out of Lipocine (LPCN) in Q2 2016, closing a stake of 6,984 shares — an estimated $1.08M sold.

Lombard Odier Asset Management (USA) first reported a position in LPCN in Q2 2014 and held it in 8 quarters. The position peaked at $4.43M in Q2 2015. 54 funds tracked by Wall St. Rank hold LPCN as of Q2 2016.

  • Lombard Odier Asset Management (USA) reported no remaining Lipocine position as of Q2 2016 after selling out during the quarter.
  • Lombard Odier Asset Management (USA) sold 6,984 Lipocine shares in Q2 2016, an estimated $1.08M.
  • Lombard Odier Asset Management (USA) first reported a position in Lipocine in Q2 2014 and held it in 8 quarters.
  • Lombard Odier Asset Management (USA)'s Lipocine position peaked at $4.43M in Q2 2015.
  • 54 funds tracked by Wall St. Rank held Lipocine as of Q2 2016.

Based on Lombard Odier Asset Management (USA)'s 13F filing for Q2 2016, filed 15 Aug 2016.